A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients

Pharmacological Research

Volumn 111, Issue , 2016, Pages 343-356

  Banach, Maciej ^a,b   Dinca, Madalina ^c   Ursoniu, Sorin ^d   Serban, Maria Corina ^d,e   Howard, George ^f   Mikhailidis, Dimitri P ^g   Nicholls, Stephen ^h   Lip, Gregory Y H ⁱ   Glasser, Stephen ^j   Martin, Seth S ^k   Muntner, Paul ^e   Rysz, Jacek ^a   Toth, Peter P ^k,l   Sahebkar, Amirhossein ^m,n  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^c Independent Pharmacist Researcher   (Belgium)

^d VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^g ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^h UNIVERSITY OF ADELAIDE   (Australia)

ⁱ UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^j University of Alabama at Birmingham   (United States)

^k JOHNS HOPKINS UNIVERSITY   (United States)

^l CGH MEDICAL CENTER   (United States)

^m MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

ⁿ UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

more..

Author keywords

Efficacy; HIV; Lipids; Safety; Statin therapy

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL MARKER;

CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIPID BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; ADULT; BLOOD; CHEMICALLY INDUCED; DYSLIPIDEMIA; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; META ANALYSIS; MIDDLE AGED; RISK FACTOR;

ADULT; ANTI-HIV AGENTS; BIOMARKERS; DYSLIPIDEMIAS; FEMALE; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 84978933125     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.06.005     Document Type: Review

References (42)

1. [1] Paisible, A.-L., Chang, C.-C.H., So-Armah, K.A., Butt, A.A., Leaf, D.A., Budoff, M., et al. HIV infection, cardiovascular disease risk factor profile, and risk for acute myocardial infarction. J. Acquir. Immune Defic. Syndr. 68 (2015), 209–216.
2. [2] Freiberg, M.S., Chang, C.C., Kuller, L.H., Skanderson, M., Lowy, E., Kraemer, K.L., et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern. Med. 173 (2013), 614–622.
3. [3] Kuller, L.H., Tracy, R., Belloso, W., De Wit, S., Drummond, F., Lane, H.C., et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med., 5, 2008, e203.
4. [4] Brown, T.T., Tassiopoulos, K., Bosch, R.J., Shikuma, C., McComsey, G.A., Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care 33 (2010), 2244–2249.
5. [5] Matta, F., Yaekoub, A.Y., Stein, P.D., Human immunodeficiency virus infection and risk of venous thromboembolism. Am. J. Med. Sci. 336 (2008), 402–406.
6. [6] Kingsley, L.A., Deal, J., Jacobson, L., Budoff, M., Witt, M., Palella, F., et al. Incidence and progression of coronary artery calcium in HIV-infected and HIV-uninfected men. AIDS 29 (2015), 2427–2434.
7. [7] Boufassa, F., Dulioust, A., Lascaux, A., Meyer, L., Boué, F., Delfraissy, J., et al. Lipodystrophy in 685 HIV-1–treated patients: influence of antiretroviral treatment and immunovirological response. HIV Clin. Trials 2 (2001), 339–345.
8. [8] Mutimura, E., Hoover, D.R., Shi, Q., Dusingize, J.C., Sinayobye, J.D.A., Cohen, M., et al. Insulin resistance change and antiretroviral therapy exposure in HIV-infected and uninfected Rwandan women: a longitudinal analysis. PLoS One, 10, 2015, e0123936.
9. [9] Zanni, M.V., Abbara, S., Lo, J., Wai, B., Hark, D., Marmarelis, E., et al. Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men. AIDS 27 (2013), 1263–1272.
10. [10] Lee, F.J., Carr, A., Dyslipidemia in HIV-Infected Patients. 2015, Springer, Dyslipidemias, 155–176.
11. [11] Hawkes, D., Jones, K.L., Smyth, R.P., Pereira, C.F., Bittman, R., Jaworowski, A., et al. Properties of HIV-1 associated cholesterol in addition to raft formation are important for virus infection. Virus Res. 210 (2015), 18–21.
12. [12] del Real, G., Jiménez-Baranda, S., Mira, E., Lacalle, R.A., Lucas, P., Gómez-Moutón, C., et al. Statins inhibit HIV-1 infection by down-regulating Rho activity. J. Exp. Med. 200 (2004), 541–547.
13. [13] Eckard, A.R., McComsey, G.A., The role of statins in the setting of HIV infection. Curr. HIV/AIDS Rep. 12 (2015), 305–312.
14. [14] Moncunill, G., Negredo, E., Bosch, L., Vilarrasa, J., Witvrouw, M., Llano, A., et al. Evaluation of the anti-HIV activity of statins. AIDS 19 (2005), 1697–1700.
15. [15] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., PRISMA Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339, 2009, b2535.
16. [16] Green, S., Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011]. 2011, The Cochrane Collaboration.
17. [17] Borenstein, M., Hedges, L., Higgins, J., Rothstein, H., Comprehensive Meta-Analysis Version 2. 2005, Biostatistics, Englewood, NJ p. 104.
18. [18] Wan, X., Wang, W., Liu, J., Tong, T., Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med. Res. Methodol., 14, 2014, 135.
19. [19] Sutton, A.J., Abrams, K.R., Jones, D.R., Jones, D.R., Sheldon, T.A., Song, F., Methods for meta-analysis in Medical Research. 2000, J. Wiley Chichester, New York.
20. [20] Duval, S., Tweedie, R., Trim and fill: a simple funnel-plot?based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56 (2000), 455–463.
21. [21] Bonnet, F., Aurillac-Lavignolle, V., Breilh, D., Pharm, D., Thiébaut, R., Peuchant, E., et al. Pravastatin in HIV-infected patients treated with protease inhibitors: a placebo-controlled randomized study. HIV Clin. Trials 8 (2007), 53–60.
22. [22] Calmy, A., Bloch, M., Wand, H., Delhumeau, C., Finlayson, R., Rafferty, M., et al. No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial. HIV Med. 11 (2010), 493–501.
23. [23] Eckard, A.R., Jiang, Y., Debanne, S.M., Funderburg, N.T., McComsey, G.A., Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J. Infect. Dis. 209 (2014), 1156–1164.
24. [24] Funderburg, N.T., Jiang, Y., Debanne, S.M., Labbato, D., Juchnowski, S., Ferrari, B., et al. Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 68 (2015), 396–404.
25. [25] Ganesan, A., Crum-Cianflone, N., Higgins, J., Qin, J., Rehm, C., Metcalf, J., et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J. Infect. Dis. 203 (2011), 756–764.
26. [26] Hürlimann, D., Chenevard, R., Ruschitzka, F., Flepp, M., Enseleit, F., Béchir, M., et al. Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing anti-retroviral combination therapy: a randomised double blind crossover trial. Heart 92 (2006), 110–112.
27. [27] Lo, J., Lu, M.T., Ihenachor, E.J., Wei, J., Looby, S.E., Fitch, K.V., et al. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV 2 (2015), e52–e63.
28. [28] Stein, J.H., Merwood, M.A., Bellehumeur, J.L., Aeschlimann, S.E., Korcarz, C.E., Underbakke, G.L., et al. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am. Heart J., 147, 2004, E18.
29. [29] Nakanjako, D., Ssinabulya, I., Nabatanzi, R., Bayigga, L., Kiragga, A., Joloba, M., et al. Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial. Trop. Med. Int. Health 20 (2015), 380–390.
30. [30] Montoya, C.J., Higuita, E.A., Estrada, S., Gutierrez, F.J., Amariles, P., Giraldo, N.A., et al. Randomized clinical trial of lovastatin in HIV-infected, HAART naive patients (NCT00721305). J. Infect. 65 (2012), 549–558.
31. [31] Moyle, G.J., Lloyd, M., Reynolds, B., Baldwin, C., Mandalia, S., Gazzard, B.G., Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS 15 (2001), 1503–1508.
32. [32] Mallon, P.W., Miller, J., Kovacic, J.C., Kent-Hughes, J., Norris, R., Samaras, K., et al. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men—a randomized, placebo-controlled study. AIDS 20 (2006), 1003–1010.
33. [33] Gili, S., Grosso Marra, W., D'Ascenzo, F., et al. Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis. Eur. Heart J., 2016, 10.1093/eurheartj/ehv734.
34. [34] Blonk, M., van Beek, M., Colbers, A., Schouwenberg, B., Burger, D., Pharmacokinetic drug–drug interaction study between raltegravir and atorvastatin 20 mg in healthy volunteers. J. Acquir. Immune Defic. Syndr. 69 (2015), 44–51.
35. [35] Cooper, R., Managing drug interactions in HIV-infected adults with comorbid illness. Can. Med. Assoc. J., 187, 2015, 36.
36. [36] Mitka, M., Exploring statins to decrease HIV-related heart disease risk. JAMA 314 (2015), 657–659.
37. [37] Fichtenbaum, C.J., Gerber, J.G., Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin. Pharmacokinet. 41 (2002), 1195–1211.
38. [38] Myerson, M., Malvestutto, C., Aberg, J.A., Management of lipid disorders in patients living with HIV. J. Clin. Pharmacol. 55 (2015), 957–974.
39. [39] Feinstein, M.J., Achenbach, C.J., Stone, N.J., Lloyd-Jones, D.M., A systematic review of the usefulness of statin therapy in HIV-infected patients. Am. J. Cardiol. 115 (2015), 1760–1766.
40. [40] Hobbs, F.D., Banach, M., Mikhailidis, D.P., Malhotra, A., Capewell, S., Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate. BMC Med., 14, 2016, 4.
41. [41] Banach, M., Aronow, W.S., Serban, M.C., Rysz, J., Voroneanu, L., Covic, A., Lipids, blood pressure and kidney update 2015. Lipids Health Dis., 14, 2015, 167.
42. [42] Gilbert, J.M., Fitch, K.V., Grinspoon, S.K., HIV-related cardiovascular disease, statins, and the REPRIEVE trial. Top. Antivir. Med. 23 (2015), 146–149.